Economic Burden Of Psoriasis Research Articles

Epidemiologic characteristics and burden of psoriasis: A multicenter, cross-sectional study.

Although psoriasis burden and treatment have been well characterized in developed countries, there are scarce in-depth epidemiological studies in Latin American countries. To describe the sociodemographic and clinical features and the economic burden of psoriasis among children and adult patients from Colombia. This cross-sectional study included patients from dermatology private practice offices, health provider institutions and hospitals in seven Colombian cities. We collected data on disease distribution, weight, height, body mass index, waist-hip ratio, disease severity, therapy, personal history of comorbidities, and direct costs. Multiple logistic regression analyses were conducted to assess the associations between severity scales and sociodemographic and clinical variables. Two-hundred-three patients (43.8% women, 56.2% men) with an age range between 7 to 89 years old were included. The main subtype was psoriasis vulgaris and mean age of diagnosis was 37.1 years. The most common comorbidities were obesity, hypertension, psoriatic arthritis, dyslipidemia and diabetes. Women had a significant increased odds of presenting with psoriatic arthritis. Body-mass-index and hypertension were significantly associated with a higher psoriasis severity, whereas being female and non-obese was associated with a lower risk. A third of the patients had a family history of psoriasis and sleeping disorders. Forty-one percent of participants either had no income or had an income below 224 US dollars per month and >20% of their income was spent on their disease. This study is supported by robust scientific data and contributes to understanding the burden of psoriasis in Latin America. This study adds well-supported data through an in-depth clinical and economical characterization of Colombian children and adult patients with psoriasis and shows the high impact and burden of the disease on patients and their families.

Clinical and economic burden of psoriasis: a retrospective study of the cost implications among cohorts in Abuja, Nigeria

<p class="abstract"><strong>Background:</strong> Psoriasis is a common chronic cutaneous inflammatory disorder of the skin which presents as sharply demarcated scaly erythematous papules or plaques. The level of its clinical severity at presentation largely determines the cost implications and economic burden on the patient. The study aimed to determine the direct cost of treating various clinical severity of psoriasis and its economic consequences to our healthcare system.</p><p class="abstract"><strong>Methods:</strong> This is a retrospective study that was conducted between May 2016 and October 2019 at the Dermatology Unit of University of Abuja Teaching Hospital. Data was retrieved from patient’s folder into a designed proforma, noting their biodata, clinical level of severity using psoriasis area severity index (PASI) score, amount of money spent on drugs, laboratory test, nursing time and consultation fees. <strong></strong></p><p class="abstract"><strong>Results:</strong> Out of 82 psoriasis patients seen during the study period, 66 fulfilled the inclusion criteria. About 51.5% of them had severe psoriasis with a mean PASI score 33.2. The annual cost of treating mild, moderate and severe psoriasis was N198,900.00, N261,633.00 and N323,708.00 respectively. This accounted for 1.77% of the national annual healthcare spending within the years under review.</p><p class="abstract"><strong>Conclusions:</strong> The cost of treating psoriasis and its economic burden is largely determined by the level of its clinical severity.</p>

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study

Background Work productivity loss (WPL) is a major contributor to the indirect costs of psoriasis. Newer biologic therapies are effective at reducing disease symptoms and improving quality of life, but their impact on WPL and associated indirect cost savings compared to previously approved biologic therapies is largely unknown. Objectives To compare the effects of guselkumab and adalimumab on WPL and associated indirect cost savings in patients with moderate-to-severe psoriasis. Methods Using data from the VOYAGE 1 (NCT02207231) trial, improvements from baseline in Dermatology Life Quality Index (DLQI) work/study domain scores were compared for patients receiving guselkumab or adalimumab at 24 and 48 weeks of treatment. Improvements in WPL and associated cost savings were calculated using a previously established DLQI-WPL algorithm. Results Among patients who could not work/study at baseline (DLQI work/study domain score = 3), a significantly greater proportion of guselkumab-treated patients could work/study without problems (DLQI work/study domain score = 0) than adalimumab-treated patients at Weeks 24 and 48. Improvements from baseline in WPL and associated cost savings were greater with guselkumab than with adalimumab at Week 48. Conclusions Guselkumab was superior to adalimumab for improvement in WPL and associated indirect cost savings, and its use may reduce the economic burden of psoriasis.

PSY28 DISEASE BURDEN AND QUALITY OF LIFE FOR PSORIASIS PATIENTS IN CHINA

Psoriasis is a common chronic inflammatory skin disease leading to psychological impacts and impairment on quality of life for patients. This study aims to investigate the psychological impact, quality of life (QoL) and economic burden of psoriasis in China. A cross-sectional survey was conducted in adult psoriasis patients in China from July to September 2018. Patients who meet the inclusion and exclusion criteria were recruited through the online-platform of psoriasis patient mutual assistance network, and filled the online questionnaire about the psychosocial impacts, direct and indirect cost in the past year. Dermatology Life Quality Index (DLQI) scale was used to assess the quality of life relating to psoriasis. Descriptive statistical analysis was conducted and analyses was stratified by DLQI level with comparisons made using the suitable tests. A total of 497 psoriasis patients were recruited in this study covering 8 geographic regions across China. The annual total expenditure of patients due to psoriasis accounted for 29.7±28.4% (Mean±SD) of the income. The annual hospitalization rate was 21.3% and length of stay was 37.0 ±44.3 days . The annual sick leave was 46.1 ±85.4 days and the unemployment rate was 37.0%. 89.1% of patients reported psychological stress . Alarmingly, 34.0% patients had suicide intention and 4.6% had suicide behavior in the past year. The average DLQI score was 13.3±7.1. 61.8% of the patients reported a severe or extremely severe impact of psoriasis on QoL (DLQI>10) and 38.2% patients reported mild or moderate impact on QoL (DLQI≤10). Comparing to the patients with DLQI≤10, patient group with DLQI>10 presented significant higher (P<0.01) disease burden for most variables. Psoriasis impose heavy economic burden, psychological morbidity and large impairment on quality of life for psoriasis patient in China. At the meanwhile, the patient with DLQI>10 have significant higher burden of psoriasis.

The economic burden of psoriasis with high comorbidity among privately insured patients in the United States

Objective: To evaluate the impact of comorbidities on healthcare resource use (HRU), and direct and indirect work-loss-related costs in psoriasis patients.Methods: Adults with psoriasis (≥2 diagnoses, the first designated as the index date) and non-psoriasis controls (no psoriasis diagnoses, randomly generated index date) were identified in a US healthcare claims database of privately-insured patients (data between January 2010 and March 2017 were used). Psoriasis patients were stratified based on the number of psoriasis-related comorbidities (0, 1–2, or ≥3) developed during the 12 months post-index. All outcomes were evaluated during the follow-up period, spanning the index date until the end of continuous health plan eligibility or data cut-off. HRU and costs per-patient-per-year (PPPY) were compared in psoriasis and non-psoriasis patients with ≥12 months of follow-up.Results: A total of 9,078 psoriasis (mean age = 44 years, 51% female) and 48,704 non-psoriasis (mean age = 41 years, 50% female) patients were selected. During the 12 months post-index, among psoriasis vs non-psoriasis patients, 71.0% vs 83.0% developed no psoriasis-related comorbidities, 26.3% vs 16.0% developed 1–2, and 2.6% vs 1.0% developed ≥3 psoriasis-related comorbidities. Compared to non-psoriasis patients, psoriasis patients had more HRU including outpatient visits (incidence rate ratios [IRRs] = 1.52, 2.03, and 2.66 for 0, 1–2, and ≥3 comorbidities, respectively [all p < 0.01]) and emergency room visits (IRRs = 1.12, 1.59, and 2.45 for 0, 1–2, and ≥3 comorbidities, respectively [all p < 0.01]) during the follow-up period. Psoriasis patients incurred greater total healthcare costs (mean cost differences [MCDs] = $1,590, $5,870, and $18,427, in patients with 0, 1–2, and ≥3 comorbidities, respectively [all p < 0.01]), and work-loss-related costs (MCDs = $335, $655, and $1,695, in patients with 0, 1–2, and ≥3 comorbidities, respectively [all p < 0.01]).Conclusions: HRU and cost burden of psoriasis are substantial, and increase with the development of psoriasis-related comorbidities.

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

ObjectivesTo describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.DesignRetrospective observational study.SettingReal-life clinical setting in 5 Italian local health units.ParticipantsA total of 351 male and female patients with at least 1 prescription for a biological drug from January 1, 2010 to December 31, 2013; patients with concomitant rheumatoid arthritis, ankylosing spondylitis, or Crohn’s disease were excluded.ResultsThe major health care cost (excluding drug costs) was represented by hospitalizations, mainly related to PSO /PsA-associated disorders and cardiometabolic disorders. Use of conventional drugs among biologics-naïve patients reached 50% in PSO and 80% in PsA; their use decreased following initiation of biological therapy. After the start of biological treatment, the incidence of hospitalization decreased both for PSO (from 12.3% to 3.2% in day hospital regimen and from 2.4% to 0.4% for conventional admission) and for PsA (from 11.1% to 8.1% and from 10.1% to 3.0%, respectively). Mean annual costs for hospitalization before biological treatment were €217 and €537 for PSO and PsA, respectively, while mean annual cost for concomitant drugs slightly increased after biologics initiation: from €249.8 to €269.4 for PSO and from €331.8 to €346.9 for PsA. The major consumption of health care resources occurred in the quarter preceding the beginning of biological treatment.ConclusionThe consumption of health resources is mostly related to hospitalization, seems to peak during the quarter before the beginning of biologics therapies, and subsequently decreases after biologics initiation. Further studies should focus on prescription scheme and economic burden of PSO and PsA in Italy to help optimize health care resources and potentiate services for patients.

The Annual Economic Burden of Psoriasis

Psoriasis is a chronic disease that affects approximately 2.2% of the U.S. population. The annual economic burden of this disease, both on an individual and national level, has not been clearly defined. Two recently published articles estimated the annual cost to be $35.2 billion (2013 $US) and $112-$135 billion (2013 $US), respectively. Notably, the two articles rely on different estimates of the 2013 U.S. psoriasis population. For patients with mild disease, the largest contributor to cost appears to be non-urgent care such as outpatient visits. For patients with moderate-to-severe disease, pharmacy costs dominate. Although we can partially explain the difference in estimates, this is not an exact science. Not all published articles include the direct, indirect, and intangible costs associated with psoriasis. The measurements themselves are subject to a degree of error. Furthermore, different estimates rely on different studies.

Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis.

Estimates of direct and indirect costs of psoriasis are limited. The aim of this study was to estimate: (i) costs in patients with psoriasis compared with controls; and (ii) impact on costs from initiating biologics. The study extracted data from Swedish administrative registers and compared 31,043 patients with 111,645 sex-, age- and residency-matched referents. Mean direct and indirect costs were estimated as US dollars (USD) 1,365 (62%) and USD 3,319 (50%) higher in patients compared with referents, respectively. The study included 352 patients treated with biologics who had at least 1-year follow-up before and after initiation of biologics. Among the 193 patients persistent with biologics for one year, 1-year costs of biologics were estimated at USD 23,293 (95% confidence interval (95% CI) 22,372-24,199). This cost was partially offset, with savings in direct cost estimated to range from USD -1135 (95% CI -2,050 to -328) to USD -4,422 (95% CI -6,552 to -2,771), depending on assumptions. The corresponding estimates for indirect costs savings were from USD -774 (95% CI -2,019-535) to USD -1,875 (95% CI -3,650 to -188). The study suggests that psoriasis is associated with substantial costs, which may be modifiable with treatment.

Cost of illness in psoriasis patients on Bath PUVA therapy versus Methotrexate

Psoriasis results in expenses to patients from many cost sources. Psoriasis treatment may result in considerable time and travelling costs, yet many studies fail to account for these costs. The objective of this study was to evaluate the economic burden of psoriasis in patients.Methods: The study was based on 200 patients with psoriasis visiting a tertiary level dermatological clinic. The data was based on a patient questionnaire and clinical data from the medical records. Item costs were based on true costs charged from the patients and all time cost estimates were done.Results: 200 patients with psoriasis were included in the study. Total costs were higher for patients receiving phototherapy than those receiving systemic treatment. The majority of the visit costs arose from hospitalization and only a small proportion were attributed to outpatient visits.Conclusion: Visit charges and other patient investigations were estimated to play a minor role in the total cost of psoriasis incurred by patients, while travel costs and loss of pay comprised the majority of the costs, which should not be omitted in future studies regarding costs of treatments.

Economic Burden of Psoriasis in the United States: A Systematic Review.

The total cost of psoriasis in the United States is unknown. Defining the US economic burden of psoriasis is needed because it provides the foundation for research, advocacy, and educational efforts. To determine the US economic burden of psoriasis from a societal perspective. PubMed and MEDLINE databases were searched between January 1, 2008, and September 20, 2013, for economic investigations on the direct, indirect, intangible, and comorbidity costs of adult psoriasis in the United States. The base year costs were adjusted to 2013 US dollars using the Consumer Price Index for All Urban Consumers and multiplied by the estimated number of US patients with psoriasis in 2013 to determine the 2013 psoriasis cost burden. Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars. Patients with psoriasis would pay a lifetime cost of $11,498 for relief of physical symptoms and emotional health; however, intangible cost data are limited. The annual US cost of psoriasis amounted to approximately $112 billion in 2013. The economic burden of psoriasis is substantial and significant in the United States.

Economic burden of psoriasis in the US significant

Economic burden of psoriasis in the US significant

Economic burden of psoriasis and obesity in patients with psoriasis in the United States

Economic burden of psoriasis and obesity in patients with psoriasis in the United States

Economic burden of psoriasis in the US

Economic burden of psoriasis in the US

Quality-of-Life Issues and Economic Burden of Psoriasis and Atopic Dermatitis

Both psoriasis and atopic dermatitis are common skin disorders that have profound social and economic effects on the patients and their families. Surveys of the effects of these diseases have demonstrated their interference with social life, sport, caring for the home, personal and sexual relationships, and the ability to work. These effects are similar across many cultures. Methods of measuring the impact of psoriasis and atopic dermatitis on quality of life include disease-specific indices such as the Psoriasis Disability Index, specialty-specific indices such as the Dermatology Life Quality Index, general health measures such as the UK Sickness Impact Profile, and utility measures. Both diseases score more highly than other skin conditions, and result in handicap levels equivalent to those experienced by patients with nondermatological diseases such as hypertension and angina. The use of these measures in psoriasis and atopic dermatitis has shown an improvement in handicap levels resulting from inpatient admission and from treatment with cyclosporin. These diseases can have an immediate effect on earnings and a long term effect on career choices and employment opportunities. Cost analysis of management strategies highlights the financial advantages of daycare outpatient treatment centres and provides a financial ranking of the different topical and systemic approaches to the treatment of psoriasis. The costs of treatment must be considered in relation to the degree of benefit gained in terms of handicap reduction and restored earning capacity, and not simply in terms of the unit cost of therapy.